Several other menin inhibitors are in development (ziftomenib, bleximenib, enzomenib etc.), and their efficacy in pediatric MEIS/HOX-dependent leukemias (such as KMT2A-r ALL/AML) needs to be seen.8 This evidence concerns the gene MEN1 and acute myeloid leukemia.